Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The Animal Antibacterial and Antibiotics Market is being driven by several key factors. Rising livestock production and ...

The University of Tennessee College of Veterinary Medicine has deployed its large animal ambulatory truck to Carter County, ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...

The University of Tennessee College of Veterinary Medicine (UTCVM) is deploying its mobile veterinary clinic to Carter County ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...